2011
DOI: 10.1126/scitranslmed.3001426
|View full text |Cite
|
Sign up to set email alerts
|

Readily Available Tissue-Engineered Vascular Grafts

Abstract: Autologous or synthetic vascular grafts are used routinely for providing access in hemodialysis or for arterial bypass in patients with cardiovascular disease. However, some patients either lack suitable autologous tissue or cannot receive synthetic grafts. Such patients could benefit from a vascular graft produced by tissue engineering. Here, we engineer vascular grafts using human allogeneic or canine smooth muscle cells grown on a tubular polyglycolic acid scaffold. Cellular material was removed with deterg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

14
492
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 493 publications
(529 citation statements)
references
References 48 publications
14
492
0
1
Order By: Relevance
“…22 Recently, the decellularization process has been utilized to develop acellular TEVG and circumvent this obstacle. 6 The nonimmunogenic properties of allogeneic extracellular matrix have been characterized in multiple animal models. 6,23,24 In this study, we utilized the ovine femoral artery model to evaluate completely biological, acellular TEVG made from fibrin remodeling by allogeneic fibroblasts in vitro as a potential solution for the clinical need of small-diameter arterial grafts.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…22 Recently, the decellularization process has been utilized to develop acellular TEVG and circumvent this obstacle. 6 The nonimmunogenic properties of allogeneic extracellular matrix have been characterized in multiple animal models. 6,23,24 In this study, we utilized the ovine femoral artery model to evaluate completely biological, acellular TEVG made from fibrin remodeling by allogeneic fibroblasts in vitro as a potential solution for the clinical need of small-diameter arterial grafts.…”
Section: Discussionmentioning
confidence: 99%
“…1 Various approaches have been used to fabricate TEVG, [3][4][5][6][7][8][9] recently reviewed. 3 Most notably in terms of clinical promise, TEVGs derived from rolling a fibroblastproduced ''cell sheet'' into a tube 5,7,8,10 and from smooth muscle cells (SMCs) seeded onto a degradable synthetic polymer tube 4,6,9 have resulted in successful implantation. In contrast to these approaches, our approach utilizes the biopolymer fibrin (in hydrogel form) as the starting scaffold, 11 which eliminates risk of any adverse host reaction to residual synthetic material.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Autologous tissue-engineered solutions have the major advantage of not requiring immunosuppression, but clinical applications are limited to static organs and tissues, such as skin, or those that can function through passive movement alone, such as trachea, heart valves, blood vessels, and bladder (4,7,12). The field continues to expand and tissue bioengineering has provided, or is close to delivering, functional human organ replacements elsewhere (6,7,(13)(14)(15)(16)(17).…”
mentioning
confidence: 99%
“…Implantation of a decellularized valve would represent a different approach, as it would require seeding of new non-contractile cells or the attraction of endogenous cells in vivo to ensure a viable implant. It is, however, a promising approach as decellularized valves have already shown functionality in vivo (Simon et al 2003;Cebotari et al 2006;Erdbrugger et al 2006;Hopkins et al 2009) and it is currently under investigation for tissue engineered constructs as well (Dahl et al 2011).…”
Section: Passive and Active Components In Tissue Retractionmentioning
confidence: 99%